Product Code: BHL1181SA
“Global Radioligand Therapy Market to Reach $16,658.4 Million by 2031.”
Market Report Coverage - Radioligand Therapy
Market Segmentation
- Product (Approved Products and Potential Pipeline)
- Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
- Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
Regional Segmentation
- North America - U.S., Canada
- Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific - Japan, South Korea, Australia, and Rest-of-Asia-Pacific
Market Growth Drivers
- Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
- Strategic Initiatives by Key Market Players
- Rise in Clinical Research Activity
Market Challenges
- High Cost Associated with Treatment and Complex Reimbursement Processes
- Increased Competition from Generics
Market Opportunities
- Expanding Radiopharmaceutical Coverage
- Role of Radioligand in Drug Discovery
Key Companies Profiled
Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc. (Progenics Pharmaceuticals), Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, Radio Medix.
Key Questions Answered in this Report:
- How is radioligand therapy revolutionizing oncology?
- What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
- What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
- How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
- What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
- What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
- How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
- Products (Approved Products and Potential Pipeline)
- Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
- Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
- Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
- What are the growth opportunities for the radioligand therapy companies in the region of their operation?
- Who are the leading players with significant offerings in the global radioligand therapy market?
- Which companies are anticipated to be highly disruptive in the future, and why?
Market Overview
Radioligand therapeutics, also known as radiopharmaceuticals, which show antitumor effects, has seen rapid development over the past decade. Although some therapies are already approved for human use, many more are in the clinical trial and will enter clinical practice in the next 2-7 years, potentially introducing new therapeutic choices for patients. Despite this innovation, several challenges remain, including supply chain, logistics, regulatory issues, and education and training. The current market for radioligand therapy is majorly dominated by manufacturers such as Novartis AG, Pfizer Inc, Johnson & Johnson Services, Inc, Telix Pharmaceuticals, Lantheus Holdings Inc., (Progenics Pharmaceuticals), Molecular Partners AG, Clovis Oncology Inc., Fusion Pharma, Point Biopharma, Precirix, ITM Isotope Technologies Munich SE, Curium Pharma, and RadioMedix. The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031.
Competitive Landscape
The global radioligand therapy market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the innovation in radioligand therapy from different sample types. Key market players of the global radioligand therapy market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2018-February 2022. The inclination of companies toward product launches and product approval suggests that the companies are involved in continuously bringing new products to the market to radioligand therapy, which is primarily attributed to a rising prevalence of cancer, rising clinical research activity, and rising key players' initiatives are driving the market.
Table of Contents
1 Research Methodology
- 1.1 Radioligand Therapy: Research Methodology
- 1.2 Primary Data Sources
- 1.3 Secondary Data Sources
- 1.4 Market Estimation Model
- 1.5 Criteria for Company Profiling
2 Radioligand Therapy Market
- 2.1 Product Definition
- 2.1.1 Inclusion and Exclusion
- 2.2 Market Scope
- 2.2.1 Scope of the Study
- 2.2.2 Key Questions Answered in the Report
- 2.3 Market Overview
- 2.3.1 Market Definition
- 2.3.2 Emerging Applications of Radioligand Therapy
- 2.3.2.1 Neuroendocrine Neoplasms
- 2.3.2.2 Prostate Cancer
- 2.3.2.3 Non-Cancerous Condition
- 2.3.3 Market Footprint and Growth Potential
- 2.3.4 COVID-19 Impact on Global Radioligand Therapy Market
- 2.3.4.1 Impact on Radioligand Therapy
- 2.3.4.2 Clinical Trial Disruptions and Resumptions
3 Industry Analysis
- 3.1 Overview
- 3.2 Challenges in Radioligand Therapy Regulatory Approval Pathway
- 3.3 Regulatory Scenario of Radioligand Therapy
- 3.4 Legal Requirements and Frameworks in the U.S.
- 3.4.1 Clinical Trial Authorization
- 3.4.2 Marketing Authorization
- 3.4.3 U.S. FDA Guidelines for NDA Submission
- 3.4.4 Post-Authorization Regulations
- 3.5 Legal Requirements and Frameworks in Europe
- 3.5.1 EMA Drug License Application Process
- 3.5.2 Centralized Procedure
- 3.5.3 Decentralized Procedure
- 3.5.4 Mutual-Recognition Procedure
- 3.5.5 National Procedure
- 3.6 Legal Requirements and Frameworks in Asia-Pacific
- 3.6.1 Legal Requirements and Frameworks in Japan
4 Pipeline Analysis
- 4.1 Radioligand Therapy Pipeline Analysis
- 4.2 Radioligand Therapy Clinical Trial Design
- 4.2.1 [Lu-177]-PNT2002
- 4.2.1.1 Product Profile
- 4.2.1.2 [Lu-177]-PNT2002 Phase III Study Design
- 4.2.1.3 [Lu-177]-PNT2002 Efficacy, Safety, and Tolerability (Phase II)
- 4.2.1.4 177Lu-PNT2002 Pharmacokinetics and Pharmacodynamics Profile (Phase I)
- 4.2.2 CAM H2
- 4.2.2.1 Product Profile
- 4.2.2.2 CAM H2 Preclinical Study Design
- 4.2.2.3 CAM H2 Phase I/IIa Clinical Study Design
- 4.2.3 [177Lu]-NeoB
- 4.2.3.1 Product Profile
- 4.2.3.2 (177Lu)-NeoB Preclinical Studies
- 4.2.3.3 (177Lu)-NeoB Phase I/II Clinical Study Design
- 4.2.4 PNT-2003
- 4.2.4.1 Product Profile
- 4.2.4.2 PNT 2003 Ongoing Phase III Clinical Study Design
- 4.2.5 ITM-11
- 4.2.5.1 Product Profile
- 4.2.5.2 ITM-11 Preclinical Proof-of-Concept Studies
- 4.2.5.3 ITM-11 Phase III Clinical Trial Design
- 4.2.6 177.Lu FAP-2286
- 4.2.6.1 Product Profile
- 4.2.6.2 177.Lu FAP, 2286 Preclinical Study Summary
- 4.2.6.3 177Lu-FAP-2286 Phase I/IIa Clinical Study Design
- 4.2.7 FPI-1434
- 4.2.7.1 Product Profile
- 4.2.7.2 FPI-1434 Preclinical Study Summary
- 4.2.7.3 FPI-1434 Phase I/IIa Clinical Study Design
- 4.2.8 FPI-1966
- 4.2.8.1 Product Profile
- 4.2.8.2 FPI-1966 Preclinical Study Summary
- 4.2.9 177Lu-DOTA-rosopatamab
- 4.2.9.1 Product Profile
- 4.2.9.2 TLX591 (177Lu-DOTA-rosopatamab) Ongoing Phase III Clinical Study Design
5 Market Dynamics
- 5.1 Overview
- 5.2 Impact Analysis
- 5.3 Market Drivers
- 5.3.1 Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
- 5.3.2 Strategic Initiatives by Key Market Players
- 5.3.3 Rise in Clinical Research Activity
- 5.4 Market Restraints
- 5.4.1 High Cost Associated with Treatment and Complex Reimbursement Processes
- 5.4.2 Increased Competition from Generics
- 5.5 Market Opportunities
- 5.5.1 Expanding Radiopharmaceutical Coverage
- 5.5.2 Role of Radioligand in Drug Discovery
6 Competitive Landscape
- 6.1 Overview
- 6.2 Product Launch
- 6.3 Product Approvals
- 6.4 Synergistic Activities
- 6.5 Mergers and Acquisitions
- 6.6 Market Share Analysis (by Company), 2020
7 Global Radioligand Therapy Market, Indication, $Million, 2020-2031
- 7.1 Overview
- 7.2 Prostate Cancer
- 7.3 Neuroendocrine Tumor (NETs)
- 7.4 Other
8 Global Radioligand Therapy Market, Products, $Million, 2020-2031
- 8.1 Overview
- 8.2 Approved Products
- 8.2.1 Lutathera
- 8.2.2 Zytiga
- 8.2.3 Xtandi
- 8.2.4 Xofigo
- 8.3 Potential Pipeline
9 Global Radioligand Therapy Market, Biomarker, $Million, 2020-2031
- 9.1 Overview
- 9.2 Prostate-Specific Membrane Antigen
- 9.3 Ki 67 Expression and Grading
- 9.4 Cytochrome P450 17A1 Inhibitor
10 Global Radioligand Therapy Market, Region, $Million, 2020-2031
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 Japan
- 10.4.2 South Korea
- 10.4.3 Australia
- 10.4.4 Rest-of-Asia-Pacific (RoAPAC)
- 10.5 Rest-of-the-World (RoW)
11 Markets - Competitive Benchmarking & Company Profiles
- 11.1 Overview
- 11.2 Johnson & Johnson Services, Inc.
- 11.2.1 Company Overview
- 11.2.2 Role of Johnson & Johnson Services, Inc. in the Global Radioligand Therapy Market
- 11.2.3 Product ASP (by Region)
- 11.2.4 Key Competitors of Company
- 11.2.5 Financials
- 11.2.6 Key Insights About the Financial Health of the Company
- 11.2.7 SWOT Analysis
- 11.3 Pfizer Inc.
- 11.3.1 Company Overview
- 11.3.2 Role of Pfizer Inc. in the Global Radioligand Therapy Market
- 11.3.3 Product ASP (by Region)
- 11.3.4 Key Competitors of Company
- 11.3.5 Financials
- 11.3.6 Key Insights About Financial Health of the Company
- 11.3.7 Business Strategies
- 11.3.7.1 Product Approval
- 11.3.8 SWOT Analysis
- 11.4 Amneal Pharmaceuticals LLC.
- 11.4.1 Company Overview
- 11.4.2 Role of Amneal Pharmaceuticals LLC. in the Global Radioligand Therapy Market
- 11.4.3 Key Competitors of Company
- 11.4.4 Financials
- 11.4.5 Key Insights About Financial Health of the Company
- 11.4.6 Business Strategies
- 11.4.7 SWOT Analysis
- 11.5 Novartis International AG
- 11.5.1 Company Overview
- 11.5.2 Role of Novartis International AG in the Global Radioligand Therapy Market
- 11.5.3 Product ASP (by Region)
- 11.5.4 Key Competitors of Company
- 11.5.5 Financials
- 11.5.6 Key Insights About Financial Health of the Company
- 11.5.7 Corporate Strategies
- 11.5.7.1 Mergers and Acquisitions
- 11.5.7.2 Synergistic Activities
- 11.5.7.3 Business Expansion and Funding
- 11.5.8 Business Strategies
- 11.5.8.1 Product Launches and Approval
- 11.5.9 SWOT Analysis
- 11.6 POINT Biopharma Global Inc
- 11.6.1 Company Overview
- 11.6.2 Role of POINT Biopharma Global Inc in the Global Radioligand Therapy Market
- 11.6.3 Key Competitors of Company
- 11.6.4 Corporate Strategies
- 11.6.5 SWOT Analysis
- 11.7 Fusion Pharma
- 11.7.1 Company Overview
- 11.7.2 Role of Fusion Pharma in the Global Radioligand Therapy Market
- 11.7.3 Key Competitors of Company
- 11.7.4 Financials
- 11.7.5 Key Insights About the Financial Health of the Company
- 11.7.6 Corporate Strategies
- 11.7.6.1 Synergistic Activities
- 11.7.7 SWOT Analysis
- 11.8 Clovis Oncology
- 11.8.1 Company Overview
- 11.8.2 Role of Clovis Oncology in the Global Radioligand Therapy Market
- 11.8.3 Key Competitors of Company
- 11.8.4 Financials
- 11.8.5 Key Insights About the Financial Health of the Company
- 11.8.6 Corporate Strategies
- 11.8.6.1 Mergers and Acquisitions
- 11.8.7 SWOT Analysis
- 11.9 Telix Pharmaceuticals
- 11.9.1 Company Overview
- 11.9.2 Role of Telix Pharmaceuticals in the Global Radioligand Therapy Market
- 11.9.3 Key Competitors of Company
- 11.9.4 Financials
- 11.9.5 Key Insights About the Financial Health of the Company
- 11.9.6 Corporate Strategies
- 11.9.6.1 Mergers and Acquisitions
- 11.9.6.2 Synergistic Activities
- 11.9.7 SWOT Analysis
- 11.1 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
- 11.10.1 Company Overview
- 11.10.2 Role of Lantheus Holdings Inc., (Progenics Pharmaceuticals) in the Global Radioligand Therapy Market
- 11.10.3 Key Competitors of Company
- 11.10.4 Financials
- 11.10.5 Key Insights About the Financial Health of the Company
- 11.10.6 Corporate Strategies
- 11.10.6.1 Mergers and Acquisitions
- 11.10.7 SWOT Analysis
- 11.11 Bayer AG
- 11.11.1 Company Overview
- 11.11.2 Role of Bayer AG in the Global Radioligand Therapy Market
- 11.11.3 Product ASP (by Region)
- 11.11.4 Key Competitors of Company
- 11.11.5 Financials
- 11.11.6 Key Insights About the Financial Health of the Company
- 11.11.7 Corporate Strategies
- 11.11.7.1 Mergers and Acquisitions
- 11.11.7.2 Product Approval
- 11.11.8 SWOT Analysis
- 11.12 Molecular Partners
- 11.12.1 Company Overview
- 11.12.2 Role of Molecular Partners in the Global Radioligand Therapy Market
- 11.12.3 Key Competitors of Company
- 11.12.4 SWOT Analysis
12 Emerging Company Profiles.
- 12.1 ITM Isotope Technologies Munich SE
- 12.1.1 Company Overview
- 12.1.2 Role of ITM Isotope Technologies Munich SE in the Global Radioligand Therapy Market
- 12.1.3 Key Competitors of Company
- 12.1.4 SWOT Analysis
- 12.2 Curium Pharma
- 12.2.1 Company Overview
- 12.2.2 Role of Curium Pharma. in the Global Radioligand Therapy Market
- 12.2.3 Key Competitors of Company
- 12.2.4 SWOT Analysis
- 12.3 Precirix
- 12.3.1 Company Overview
- 12.3.2 Role of Precirix in the Global Radioligand Therapy Market
- 12.3.3 Key Competitors of Company
- 12.3.4 SWOT Analysis
- 12.4 Radio Medix
- 12.4.1 Company Overview
- 12.4.2 Role of Radio Medix in the Global Radioligand Therapy Market
- 12.4.3 Key Competitors of Company
- 12.4.4 SWOT Analysis